XML 63 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment and Geographic Data
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment and Geographic Data SEGMENT AND GEOGRAPHIC DATA
On January 1, 2024 we adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which expands disclosure requirements to require entities to disclose significant segment expenses that are regularly provided to or easily computed from information regularly provided to the chief operating decision maker. We have updated our disclosures to include our significant segment expenses that are regularly provided to our chief operating decision maker (CODM).
We segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics which aligns to our internal reporting structure and how our CODM assesses the performance of and allocates resources. The CODM is the Chief Executive Officer. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using segment operating income. Our reportable segments and related disclosures reflect certain reclassifications of prior year amounts from our Orthopaedics segment to our MedSurg and Neurotechnology segment due to changes in our internal reporting structure.
The Corporate and Other category shown in the table below includes corporate and administration, corporate initiatives and share-based compensation, which includes compensation related to employee stock options, restricted stock units and performance stock unit grants and director stock options and restricted stock unit grants.
Segment Results202420232022
MedSurg and Neurotechnology$13,518 $12,163 $10,893 
Orthopaedics$9,077 8,335 7,556 
Net sales$22,595 $20,498 $18,449 
MedSurg and Neurotechnology$5,320 $4,876 $4,637 
Orthopaedics$2,400 2,254 1,920 
Cost of sales $7,720 $7,130 $6,557 
MedSurg and Neurotechnology$784 $702 $682 
Orthopaedics$540 508 477 
Segment research, development and engineering expenses$1,324 $1,210 $1,159 
MedSurg and Neurotechnology$3,203 $2,934 $2,564 
Orthopaedics$3,111 2,922 2,608 
Segment selling, general and administrative expenses $6,314 $5,856 $5,172 
MedSurg and Neurotechnology$208 $181 $178 
Orthopaedics433 386 350 
Segment depreciation and amortization $641 $567 $528 
Corporate and Other162 139 123 
Amortization of intangible assets623 635 627 
Total depreciation and amortization$1,426 $1,341 $1,278 
MedSurg and Neurotechnology$4,004 $3,470 $2,831 
Orthopaedics2,591 2,265 2,202 
Segment operating income$6,595 $5,735 $5,033 
Items not allocated to segments:
Corporate and Other$(880)$(780)$(649)
Inventory stepped up to fair value(46)— — 
Acquisition and integration-related charges(108)(20)(138)
Amortization of intangible assets(623)(635)(627)
Structural optimization and other special charges(138)(170)(295)
Goodwill and other impairments(977)(36)(270)
Medical device regulation(58)(96)(140)
Recall-related matters(40)(18)15 
Regulatory and legal matters(36)(92)(76)
Consolidated operating income$3,689 $3,888 $2,841 
Segment Assets and Capital Spending
Assets:20242023
MedSurg and Neurotechnology$23,115 $20,804 
Orthopaedics18,507 18,023 
Total segment assets$41,622 $38,827 
Corporate and Other1,349 1,085 
Total assets$42,971 $39,912 
Purchases of property, plant and equipment:202420232022
Orthopaedics$230 $179 $173 
MedSurg and Neurotechnology276 183 175 
Total segment purchases of property, plant and equipment$506 $362 $348 
Corporate and Other249 213 240 
Total purchases of property, plant and equipment$755 $575 $588 
We measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges, structural optimization and other special charges, goodwill and other impairments, reserves for certain product recall matters and reserves for certain legal and regulatory matters. Identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. Corporate assets are principally property, plant and equipment and noncurrent assets.
The countries in which we have local revenue generating operations have been combined into the following geographic areas: the United States; Europe, Middle East, Africa; Asia Pacific; and other foreign countries, which include Canada and countries in the Latin American region. Net sales are reported based on the geographic area of the Stryker location where the sales to the customer originated.
Geographic Information
Net SalesNet Property, Plant and Equipment
20242023202220242023
United States$16,943 $15,257 $13,638 $1,997 $1,874 
Europe, Middle East, Africa2,897 2,618 2,348 1,260 1,151 
Asia Pacific2,020 1,946 1,885 75 77 
Other countries735 677 578 116 113 
Total$22,595 $20,498 $18,449 $3,448 $3,215